|
|
Asympt pt on LHRH agonist for PSA-only recurrence dvlps isolated bone, LN mets. Tx?Asympt pt on LHRH agonist for PSA-only recurrence dvlps isolated bone, LN mets. Tx?An otherwise healthy 62-year-old asymptomatic man receiving an LHRH agonist for PSA-only recurrent prostate cancer (PSADT How would you care for the same patient if he were 80 years old?
Dawson NA et al. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Expert Opin Biol Ther 2014;14(5):709-19. Abstract Hampson LA et al. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015;[Epub ahead of print]. Abstract Liu C et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res 2015;[Epub ahead of print]. Abstract Lorente D et al. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol 2015;12(1):37-47. Abstract Mohsen B et al. Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: Systematic review and meta-analysis of the literature. BJU Int 2013;112(8):1062-72. Abstract Smith MR et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 2015;26(2):368-74. Abstract Vadhan-Raj S et al. Clinical benefit in patients with metastatic bone disease: Results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012;23(12):3045-51. Abstract Zhang T et al. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 2014;[Epub ahead of print]. Abstract |
12 months) develops an isolated bone and lymph node metastasis. What treatment would you likely recommend (with or without bone-targeted treatment)?